4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-chloroquinoline | 444576-78-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-chloroquinoline
• 英文别名: 7-chloro-N-[3-(2-nitroimidazol-1-yl)propyl]quinolin-4-amine
• CAS: 444576-78-7
• 化学式: C₁₅H₁₄ClN₅O₂
• 分子量: 331.761
• InChiKey: PDSVGSZYJOFNPR-UHFFFAOYSA-N

物化性质

• 沸点：
  610.1±65.0 °C(Predicted)
• 密度：
  1.45±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  88.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-chloroquinoline 在 盐酸 作用下， 以 乙醚 、 丙酮 为溶剂， 以100%的产率得到NLCQ-1
  参考文献：
  名称：

  Method of Treating Latent Tuberculosis

  摘要：

  本发明揭示了2-硝基咪唑基-烷基氨基喹啉及其含量，对于治疗结核病有用。本发明还揭示了使用2-硝基咪唑基-烷基氨基喹啉及其含量治疗结核病的方法。

  公开号：

  US20080076797A1
• 作为产物：
  描述：

  4,7-二氯喹啉 在 potassium fluoride 作用下， 以 丙醇 、 二甲基亚砜 为溶剂， 反应 26.0h， 生成 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-chloroquinoline
  参考文献：
  名称：

  Method of Treating Latent Tuberculosis

  摘要：

  本发明揭示了2-硝基咪唑基-烷基氨基喹啉及其含量，对于治疗结核病有用。本发明还揭示了使用2-硝基咪唑基-烷基氨基喹啉及其含量治疗结核病的方法。

  公开号：

  US20080076797A1

文献信息

• Bacterial nitroreductase enzymes and methods relating thereto
  申请人：Guise Christopher Paul

  公开号：US10357577B2

  公开（公告）日：2019-07-23

  The invention relates generally to bacterial nitroreductase enzymes and methods of use thereof: more particularly, although not exclusively, the enzymes have use in non-invasive imaging techniques, monitoring of therapeutic cell populations and gene-directed enzyme prodrug therapy. The invention also relates to the use of bacterial nitroreductase enzymes in radioimaging and/or ablation of biological agents and to compositions of use in such methods.

  本发明一般涉及细菌硝基还原酶及其使用方法：更具体地说，尽管不完全是，这种酶可用于非侵入性成像技术、治疗细胞群监测和基因导向酶原药治疗。本发明还涉及细菌硝基还原酶在放射成像和/或生物制剂消融中的应用，以及在此类方法中的使用组合物。
• Compounds and methods for treatment of solid tumors
  申请人：Barbeau Donald L.

  公开号：US20090239820A1

  公开（公告）日：2009-09-24

  The present invention relates to pharmaceutical compositions containing targetable bioconjugates of hydralazine, a direct vasodilating agent previously shown to decrease tumor blood flow, oxygenation and interstitial fluid pressure in solid tumors. These bioconjugates are hydralazine prodrugs that contain hydralazine conjugated to biocompatible carrier molecules which specifically bind to sites that are expressed on a diverse variety of tumor cell types. These hydralazine prodrugs are preferably conjugated through an acid-labile hydrazone link that is designed to be stable in plasma and release hydralazine through acid-catalyzed hydrolysis in the acidic environment of the target tumor. Because these prodrugs are stable at physiological pH and in plasma, they are devoid of systemic vasoactive activity; however, they are acid-labile conjugates that can be hydrolyzed upon reaching the more acid environment of the tumor where the vasoactive activity of hydralazine is restored. These prodrugs selectively bind to tumor-specific receptors on tumor cells, and are degraded in the acidic tumor cell environment or the acidic lysosomal compartments after being internalized into the cell.
• BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO
  申请人：Guise Christopher Paul

  公开号：US20130295011A1

  公开（公告）日：2013-11-07

  The invention relates generally to bacterial nitroreductase enzymes and methods of use thereof: More particularly, although not exclusively, said enzymes have use in non-invasive imaging techniques, monitoring of therapeutic cell populations and gene-directed enzyme prodrug therapy. The invention also relates to the use of bacterial nitroreductase enzymes in radioimaging and/or ablation of biological agents and to compositions of use in such methods.
• US7618986B2
  申请人：——

  公开号：US7618986B2

  公开（公告）日：2009-11-17
• US8778892B2
  申请人：——

  公开号：US8778892B2

  公开（公告）日：2014-07-15